Targeted therapy of advanced colorectal cancer / 国际肿瘤学杂志
Journal of International Oncology
; (12): 391-394, 2016.
Article
em Zh
| WPRIM
| ID: wpr-489647
Biblioteca responsável:
WPRO
ABSTRACT
Targeted agents for advanced colorectal cancer mainly include inhibitors of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR).Studies show that bevacizumab and cetuximab can improve the prognosis of advanced colorectal cancer patients,but there is slight difference in the choice of chemotherapy regimens when combined with them.Bevacizumab and cetuximab can improve the overall survival of K-ras wild-type colorectal cancer patients similarly.The emergence of new targeted drugs such as aflibercept,regorafenib provides more choices for the targeted therapy of advanced colorectal cancer patients.
Texto completo:
1
Índice:
WPRIM
Tipo de estudo:
Prognostic_studies
Idioma:
Zh
Revista:
Journal of International Oncology
Ano de publicação:
2016
Tipo de documento:
Article